Nasdaq
$11.18▲ 1.36%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $569.1MShares out 50.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 10.7Overnight26.10.07 10:37SCHEDULE 13D/AOwnership#●●●#●●●
PUMA BIOTECHNOLOGY, INC.
This is a Schedule 13D/A filing submitted by Alan H. Auerbach regarding Puma Biotechnology, Inc. The reporting person has updated their beneficial ownership status in the company, reflecting changes in significant shareholder holdings.…more
$11.18+1.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.17Overnight26.09.17 10:134Ownership
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology, Inc. (PBYI) insider Troy Edward Wilson filed a Form 4 report regarding changes in beneficial ownership of securities as of September 14, 2026. This filing serves as an official notification of the insider's equity transaction.…more
$11.18+1.36%vs prev closeView filingShare - 9.17Overnight26.09.17 10:064Ownership
PUMA BIOTECHNOLOGY, INC.
Alessandra Cesano, an executive at Puma Biotechnology, reported a change in her beneficial ownership of company shares as of September 14, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more
$11.18+1.36%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.17After-hours26.09.18 05:10#●●●#●●●
Puma Biotechnology Initiates Phase II Trial for Small Cell Lung Cancer
Puma Biotechnology has launched a Phase II clinical trial evaluating the combination of alisertib and paclitaxel for patients with advanced small cell lung cancer. The study aims to assess the safety, tolerability, and clinical efficacy of the treatment regimen.…more
$11.18+1.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga